Simultaneous neutralization of Ang-2 and VEGF-A with faricimab has the potential to reduce vascular destabilization in age-related macular degeneration, achieving sustained efficacy with a significantly lower frequency of administration as compared with ranibizumab.
The results of the STAIRWAY phase 2 multicenter controlled trial, presented at the virtual Association for Research in Vision and Ophthalmology meeting, showed promising results, according to one presenter.
Ang-2 is a pro-inflammatory mediator that acts synergistically with VEGF to drive vascular instability.
“Faricimab is the
Uncategorized